(1)$双鹭药业(SZ002038)$ 来那度胺(立生)晶型与$新基制药(CELG)$ 来那度胺(瑞复美)晶型不同,可以挑战新基专利。
(2)...查看全文
牛氓的胜利2018-07-29 16:26
$新基制药(CELG)$来那度胺(瑞复美)全球销售数据最新出炉。
2018年第二季度,瑞复美单季度全球销售额同比增长20%,美国本土销售额同比增长14%, 美国以外其他规范市场(欧洲、南美、澳洲、日本、韩国、中国)同比增长
28.25%。
从今年开始,中国各省市执行《2017年新版医保目录》和《...查看全文
牛氓的胜利2018-07-29 16:21
$新基制药(CELG)$来那度胺(瑞复美)全球销售数据出炉,2018年第二季度,瑞复美单季度全球销售额增长20%,美国本土销售额增长14%, 美国以外其他规范市场(欧洲、南美、澳洲、日本、韩国、中国)增长28.25%。
因为从今年开始,中国各省市执行《新版医保目录和谈判品种支付标准》,很容易联想到...查看全文
张小丰2018-07-28 20:41
$新基制药(CELG)$ 昨天把新基的Q2电话会议读完。
感觉这2个月形式还不错。有几个研发的成功的好消息。整体来看CEO的语气没有这么慌了。 这2年会有5个药物进入报产阶段。 如果能全部顺利获批那么投资者对于来拉度胺的专利悬崖的应对会心中有底一点。查看全文
$新基制药(CELG)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013792 Size: 69 KB 网页链接
$新基制药(CELG)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-20-013796 Size: 42 KB 网页链接
$新基制药(CELG)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-19-022527 Act: 34 Size: 15 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022225 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022228 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-4 POS Securities issued, formation of bank or savings and loan holding company [General Instruction G], post-effective amendments Accession Number: 0001140361-19-022200 Act: 33 Size: 20 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022201 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022206 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022210 Act: 33 Size: 39 KB 网页链接
$新基制药(CELG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001140361-19-022217 Act: 33 Size: 39 KB 网页链接